iMDK quarterhydrate

iMDK quarterhydrate is a potent PI3K inhibitor and inhibits the growth factor MDK (also known as midkine or MK). iMDK quarterhydrate suppresses non-small cell lung cancer (NSCLC) cooperatively with A MEK inhibitor without harming normal cells and mice Appearance:SolidIn Vitro:iMDK (50-500 nM) quarterhydrate suppressed AKT phosphorylation in a dose-dependent manner in H441 lung adenocarcinoma cells after treatment for 72 h. In contrast, iMDK quarterhydrate robustly increases p-ERK. MCE has not independently confirmed the aIn Vivo:The combination treatment of iMDK ( (9mg/kg/day; intraperitoneally injected with 100 μl) and PD0325901 (5mg/kg; orally administered) effectively reduced lung tumor growth in a xenograft mouse model. MCE has not independently confirmed the accuracyBiological Activity:iMDK quarterhydrate is a potent PI3K inhibitor and inhibits the growth factor MDK (also known as midkine or MK). iMDK quarterhydrate suppresses non-small cell lung cancer (NSCLC) cooperatively with A MEK inhibitor without harming normal cells and mice.

Specifications and Purity: ≥99%

Molecular Formula: C21H13FN2O2S.1/4H20

Molecular Weight: 380.91